Fig. 1

Patient satisfaction with efficacy dimensions of fremanezumab^a. CM, chronic migraine; EM, episodic migraine. ^aPatients responded to the following question: “Thinking specifically of the experimental medicine’s ability to prevent migraine, with which dimension of your migraine relief were you satisfied? Select all that apply.” This question had the following response options: “reducing attack frequency,” “reducing migraine pain intensity,” “reducing attack duration,” “reducing migraine-associated symptoms (like nausea, light & sound sensitivity),” “reducing migraine associated disability (ability to work and participate in activities),” and “none of the above”